High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination
Authors:
- Tuuli MetsvahtTMTuuli Metsvaht
- Georgi NellisGNGeorgi Nellis
- Heili VarendiHVHeili Varendi
- Anthony J NunnANAnthony J Nunn
- Susan GrahamSGSusan Graham
- Andre RieutordARAndre Rieutord
- Thomas StormeTSThomas Storme
- James McElnayJMJames McElnay
- Hussain MullaHMHussain Mulla
- Mark A TurnerMTMark A Turner
- Irja LutsarILIrja Lutsar
Open Access
- 16 April 2015
- journal article
- research article
- Published by Springer Nature in BMC Pediatrics
- Vol. 15 (1) , 41
Abstract
Antibiotic dosing in neonates varies between countries and centres, suggesting suboptimal exposures for some neonates. We aimed to describe variations and factors influencing the variability in the dosing of frequently used antibiotics in European NICUs to help define strategies for improvement. A sub-analysis of the European Study of Neonatal Exposure to Excipients point prevalence study was undertaken. Demographic data of neonates receiving any antibiotic on the study day within one of three two-week periods from January to June 2012, the dose, dosing interval and route of administration of each prescription were recorded. The British National Formulary for Children (BNFC) and Neofax were used as reference sources. Risk factors for deviations exceeding ±25% of the relevant BNFC dosage recommendation were identified by multivariate logistic regression analysis. In 89 NICUs from 21 countries, 586 antibiotic prescriptions for 342 infants were reported. The twelve most frequently used antibiotics – gentamicin, penicillin G, ampicillin, vancomycin, amikacin, cefotaxime, ceftazidime, meropenem, amoxicillin, metronidazole, teicoplanin and flucloxacillin – covered 92% of systemic prescriptions. Glycopeptide class, GA <32 weeks, 5th minute Apgar score <5 and geographical region were associated with deviation from the BNFC dosage recommendation. While the doses of penicillins exceeded recommendations, antibiotics with safety concerns followed (gentamicin) or were dosed below (vancomycin) recommendations. The current lack of compliance with existing dosing recommendations for neonates needs to be overcome through the conduct of well-designed clinical trials with a limited number of antibiotics to define pharmacokinetics/pharmacodynamics, efficacy and safety in this population and by efficient dissemination of the results.Keywords
This publication has 44 references indexed in Scilit:
- Safety of fluconazole in paediatrics: a systematic reviewEuropean Journal of Clinical Pharmacology, 2013
- Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infectionsEuropean Journal of Clinical Pharmacology, 2012
- Short versus Long Infusion of Meropenem in Very-Low-Birth-Weight NeonatesAntimicrobial Agents and Chemotherapy, 2012
- European survey on the use of prophylactic fluconazole in neonatal intensive care unitsEuropean Journal of Pediatrics, 2011
- Ciprofloxacin safety in paediatrics: a systematic reviewArchives of Disease in Childhood, 2011
- Comparison of ampicillin plus gentamicin vs. penicillin plus gentamicin in empiric treatment of neonates at risk of early onset sepsisActa Paediatrica, 2010
- Meropenem Pharmacokinetics in the NewbornAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetics of Penicillin G in Infants with a Gestational Age of Less than 32 WeeksAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetics of Penicillin G in Very-Low-Birth-Weight NeonatesAntimicrobial Agents and Chemotherapy, 2007
- VancomycinClinical Pharmacokinetics, 2004